may have noticed uh some of the pharmaceutical names have moved up sharply in the last few minutes. We've got some breaking news out of Washington on drug pricing. Aean Jabers has the details perhaps filling us in on why we've seen this move.Aean. Yeah, David. It is pharmaceutical related.Uh and we don't have all the details right now. We're trying to solve a mystery in real time here, which is that the president has an event on his calendar at 11:00 a. m.just scheduled as an announcement. Uh and the questi ...

may have noticed uh some of the pharmaceutical names have moved up sharply in the last few minutes. We've got some breaking news out of Washington on drug pricing. Aean Jabers has the details perhaps filling us in on why we've seen this move.Aean. Yeah, David. It is pharmaceutical related.Uh and we don't have all the details right now. We're trying to solve a mystery in real time here, which is that the president has an event on his calendar at 11:00 a. m.just scheduled as an announcement. Uh and the questi ...

Watch live coverage as President Trump announces a deal with Pfizer on lowering drug prices. For more context and news coverage of the most important stories of our day, click here: https://www.nbcnews.com » Subscribe to NBC News: http://nbcnews.to/SubscribeToNBC » Watch more NBC video: http://bit.ly/MoreNBCNews NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features NBCNews.com, MSNBC.com, TODAY.com, Night ...

Pharma companies are expected to submit plans to the Trump administration today for voluntarily lowering drug prices. Angelica Peebles joins us right now with more on the deadline that's approaching and what's happening behind the scenes. Angelica, what are you hearing.Yeah, Becky. Well, so far we haven't heard companies making many concrete promises. Most are telling us that they're in talks with the administration and that they don't have anything to share yet.We've heard a number of CEOs like Lily's Dave ...

This Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricing https://t.co/a1bmbDi1RS ...

Core Viewpoint - Investors are increasingly concerned about the lack of clarity regarding drug pricing, which is creating uncertainty in the market [1] Group 1 - The ambiguity in drug pricing is causing unease among investors [1] - This uncertainty may impact investment decisions and market stability [1]

Joining us now, Courtney Breen, senior analyst at Bernstein, covering US Pharma, Bioarma. Courtney, great to have you with us. Um, obviously there's still some some questions outstanding.I'm I'm wondering if you're you know, as you think about companies with US manufacturing, if companies have pre-existing plants, are they also exempt. I think what we've had so far is a a tweet or a post uh on on truth social rather than necessarily the discreet and detailed policy. So I think there are a lot of questions t ...

This Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricing https://t.co/a1bmbDi1RS ...

This Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricinghttps://t.co/OqK5Yd7WE1 https://t.co/eBccIgcbgG ...

we're seeing you and other companies pulling back from the UK. You know, just last week saw that you were pausing um one of your investments there. So, what's happening in the UK and you know, should that send a message to policy makers here in the US.>> Probably it should. I mean, I think uh the UK has been on a a long slow glide path from a leader in biofarmaceuticals to really a lagard and that's happened over the last 20 years through a number of policy mistakes. Um the most important one is that their ...